Ambamustine in the Second-Line Treatment of Patients With Small-Cell Lung Cancer

Reporting results of cancer treatment

1981 • 7,916 citations

Optimal two-stage designs for phase II clinical trials

1989 • 3,494 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

1997 • 474 citations

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

1992 • 443 citations

Alkylating agents in bronchogenic carcinoma

1969 • 353 citations

Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.

1995 • 178 citations

Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)

1994 • 144 citations

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.

1996 • 132 citations

Activity of docetaxel (Taxotere) in small cell lung cancer

1994 • 130 citations

Management of small-cell cancer of the lung

1992 • 84 citations

Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients.

1992 • 67 citations

Second line chemotherapy in small cell lung cancer

1989 • 28 citations

Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas

1989 • 14 citations

Strategies for new drug identification in small cell lung cancer

1993 • 4 citations